30 closest matches · ranked by relevance
Pharmacokinetics of Avycaz in ICU Patients
Primary: Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients — 34 Liter
Bacterial Infections
Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL
Gram-Negative Bacterial Infections
Primary: Probability of Target Attainment for 40% fT>MIC — 100; 100 percentage of time above MIC
Bacterial Infection
Primary: Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event — 1; 0; 0; 1 Participants
Cystic Fibrosis
Primary: Peak Plasma Concentration (Cmax) — 85.87 mg/L
Sepsis
Primary: Imipenem Clearance — 17.31 L/h
Renal Insufficiency
Primary: Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM) — 922.9; 733.5 Microgram*hour per…
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Sepsis
Primary: Imipenem Clearance — 15.21 Liters per hour
Septic Shock
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 10 participants
Systemic Infections
Primary: Pharmacokinetic Parameters of Avibactam and Ceftazidime for Cohort 1 and 2: AUC — 35140; 219100; 33590; 212400 h*ng/mL
Systemic Fungal Infections
Primary: Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose — 17932 ng*h/mL
Cystic Fibrosis · Cystic Fibrosis Pulmonary Exacerbation · Pseudomonas Aeruginosa Infection
Primary: Ceftolozane Clearance — 4.76 Liters per hour
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Cystic Fibrosis
Primary: Blood-plasma Concentration of Piperacillin — 21; 21 mg/L
Surgical Site Infection · Vancomycin
Primary: Pharmacokinetics Analysis: V˅c — 2.56; 1.14 L
Critically Ill · Pneumonia
Primary: Maximum Plasma Concentration (Cmax) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment…
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Complicated Intra-Abdominal Infections, cIAIs
Primary: Plasma Concentration of Aztreonam (ATM): Sparse Sampling at Day 1, 0 hr — 0.1 microgram per milliliter (mcg/mL)
Bacterial Infection
Primary: Calculated Exposure Measures for Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24) — 24.3 mg·hr/L
Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Clinical Modified Intent-to-Treat (cMITT) Population — 62.7 Percentage of participants
Cystic Fibrosis · Pneumonia · Pseudomonas Aeruginosa Infection
Primary: Population Pharmacokinetics - Total Body Clearance — 0.36 L/hr/kg
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 52.5; 59.1; 8.2; 4.5 percentage of participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose) — 193.33; 165.70 mcg/mL
Sepsis
Primary: Volume of Distribution (Vd) — 28.52 liters
Focus of the Study:Protein Binding Characteristics of Voriconazole.
Primary: Differences in Overall Protein Binding in the Presence of Different Plasma Albumin Concentrations. — 49.1; 49.6 % of plasma protein binding
Obesity
Primary: Serum Maximum Concentrations for Piperacillin — 136; 190; 237; 332 milligrams per liter
Obesity · Critical Illness
Primary: Plasma Concentration of Levofloxacin — 76 mg/L*hr